Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Lagevrio TM
Active ingredients: molnupiravir
What it is used for
LAGEVRIO (molnupiravir) has provisional approval for the treatment of adults with COVID- 19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk for hospitalisation or death [see Section 5.1 PHARMACODYNAMIC PROPERTIES Clinical Trials].,The decision to approve this indication has been made on the basis of the analysis of efficacy and safety data from a Phase 3 trial. Continued approval of this indication depends on additional data.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Swedish Orange opaque capsule with the corporate logo and 82 printed with white ink
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient molnupiravir
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
Top results
TGA provisionally approves two oral COVID-19 treatments, molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID) | Therapeutic Goods Administration (TGA)
The TGA has granted provisional approval to two oral COVID-19 treatments.
Read more on TGA – Therapeutic Goods Administration website
COVID-19 antiviral medicine - Better Health Channel
Antivirals are available for eligible people to treat COVID-19.
Read more on Better Health Channel website
Oral treatments for COVID-19 | Australian Government Department of Health and Aged Care
Learn about the different oral treatments available for COVID-19 and how to access them.
Read more on Australian Government Department of Health and Aged Care website
What you need to know about COVID-19 - Immunisation Coalition
What you need to know about COVID-19 so you can protect yourself, your friends, family and the rest of the community.
Read more on Immunisation Coalition website
COVID-19 antivirals – your questions answered | NSW Government
Answers to frequently asked questions about COVID-19 antiviral medicines.
Read more on NSW Health website
Top results
RACGP - What GPs need to know about the new COVID antivirals
Reproduced with permission from The Royal Australian College of General Practitioners
Read more on RACGP - The Royal Australian College of General Practitioners website
